FDA Ignored Device Reclassification Process, DC Circ. Told

Law360, Washington (April 8, 2014, 3:23 PM EDT) -- ReGen Biologics Inc. urged a D.C. Circuit panel on Tuesday to nix a U.S. Food and Drug Administration decision reclassifying its knee implant device as not being substantially similar to others on the market, an action the company claims drove it into bankruptcy, saying the agency should have undergone a full notice and comment process to reach that conclusion.

According to ReGen, the FDA ignored its congressionally mandated device reclassification procedures when it revoked its initial determination that the collagen meniscus implant at issue was substantially...
To view the full article, register now.

Related

Sections

Case Information

Case Title

Ivy Sports Medicine, LLC v. Sylvia Mathews Burwell, et al


Case Number

13-5139

Court

Appellate - DC Circuit

Nature of Suit

2890 Other Statutory Actions

Date Filed

May 14, 2013

Law Firms

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.